Cancer Chemotherapy and Pharmacology

, Volume 36, Issue 4, pp 271–278 | Cite as

Intracellular glutathione and cytotoxicity of platinum complexes

  • L. Pendyala
  • P. J. Creaven
  • R. Perez
  • J. R. Zdanowicz
  • D. Raghavan
Original Article Glutathione, Cytotoxicity Platinum

Abstract

Although there have been a number of reports correlating cellular GSH levels with cytotoxicity of platinum agents, none has examined the relationship between GSH concentrations and cytotoxicity. In this study, using a highly specific HPLC method for measuring GSH and expressing GSH as concentration and also per cell number, we evaluated the correlation between GSH levels and the cytotoxicity to five agents in ten human tumor cell lines. The five platinum agents included the platinum(II) complexes cisplatin, carboplatin and oxaliplatin and platinum(IV) complexes iproplatin and tetraplatin. The correlation between intracellular GSH concentration and cytotoxicity was highly significant only for iproplatin (P=0.002) followed by tetraplatin, which demonstrated a trend toward statistical significance (P=0.06). Cytotoxicity of the other platinum complexes showed no relation to GSH concentration, cisplatin itself showing aP-value of 0.09. In contrast, the GSH levels normalized to cell number showed a statistically significant correlation with the cytotoxicity of four of the five platinum agents, the exception being carboplatin; the strongest correlation observed was that for iproplatin and tetraplatin. Glutathione-S-transferase (GST) activity in these cell lines showed no correlation with cytotoxicity of any of the platinum complexes. Our results, from the analyses of both GSH concentration as well as GSH per cell number, suggest a significantly higher interaction between GSH and iproplatin compared with the other platinum agents. Moreover, our data suggest that relationships between cytotoxicity and GSH levels on a per-cell basis may not persist when differences in cell volume are taken into account.

Key words

Glutathione Cytotoxicity Platinum 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ali-Osman F, Rairkar A (1992) Alterations in DNA polymerases α, β and δ in human brain tumor cells after glutathione depletion. Proc Am Assoc Cancer Res 33: 497Google Scholar
  2. 2.
    Anderson ME (1985) Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 113: 548Google Scholar
  3. 3.
    Andrews PA, Murphy MP, Howell SB (1986) Cellular resistance to platinating agents in ovarian carcinoma. In: Hall TC (ed) Cancer drug resistance. Alan R. Liss, New York, p 115Google Scholar
  4. 4.
    Andrews PA, Murphy MP, Howell SB (1989) Characterization of cisplatin resistance in COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol 25: 619Google Scholar
  5. 5.
    Bailey HH, Gipp JJ, Ripple M, Wilding G, Mulcahy RT (1992) Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res 52: 5115Google Scholar
  6. 6.
    Bedford P, Walker MC, Sharma HL, Perera A, McAuliffe CA, Masters J, Hill BT (1987) Factors influencing the sensitivity of two human bladder carcinoma cell lines to cisdiamminedichloroplatinum (II). Chem Biol Interact 61: 1Google Scholar
  7. 7.
    Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, et al (1987) Characterization of a cis-diamminedichloroplatinum (II) resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414Google Scholar
  8. 8.
    Bolton MG, Colvin OM, Hilton J (1991) Specificity of isozymes of murine hepatic glutathione-S-transferase for the conjugation of glutathione with melphalan. Cancer Res 51: 2410Google Scholar
  9. 9.
    Borch RF, Dedon PC, Gringeri A, Montine TJ (1987) Inhibition of platinum drug toxicity by diethyldithiocarbamate. In: Nicolini M (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Martinus Nijhoff Publishing, Boston, p 216Google Scholar
  10. 10.
    Chaney SG, Gibbons GR, Wyrick SD, Podhasky P (1991) An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV)(tetraplatin) in the L1210 cell line. Cancer Res 51: 969Google Scholar
  11. 11.
    Chen G, Zeller WJ (1991) Augmentation of cisplatin cytotoxicity in vivo by DL-buthionine sulfoximine in DDP sensitive and resistant rat ovarian tumors and its relation to DNA interstrand cross links. Anticancer Res 11: 2231Google Scholar
  12. 12.
    Ciaccio PJ, Tew KD, Lacreta FP (1990) The spontaneous and glutathione transferase mediated reaction of chlorambucil and glutathione. Cancer Commun 2: 279Google Scholar
  13. 13.
    Deleve LD, Kaplowitz N (1991) Glutathione metabolism and its role in hepatotoxicity. Pharmacol Ther 52: 287Google Scholar
  14. 14.
    Eastman A (1987) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34: 155Google Scholar
  15. 15.
    Eastman A, Schulte N, Sheibani N, Sorenson CM (1987) Mechanisms of resistance to platinum drugs. In: Nicolini M (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Martinus Nijhoff Publishing, Boston, p 178Google Scholar
  16. 16.
    Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82: 70Google Scholar
  17. 17.
    Eva A, Robbins KC, Anderson PR, Srinivasan A, Tronick SR (1982) Cellular genes analogous to retroviral onc genes are transcribed in human tumor cells. Nature 295: 116Google Scholar
  18. 18.
    Fahey RC, Newton GL (1985) Determination of low molecular weight thiols using monobromobimane fluorescent labelling and high performance liquid chromatography. Methods Enzymo 113: 85Google Scholar
  19. 19.
    Fogh J, Trempe G (1975) New human tumor cell lines. In: Fogh J (ed) Human tumor cells in vitro. Plenum Press, New York, p 115Google Scholar
  20. 20.
    Fogh J, Fogh JM, Orfeo T (1977) One hundred and twenty seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59: 221Google Scholar
  21. 21.
    Fogh J, Wright WC, Loveless JD (1977) Absence of Hela cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58: 209Google Scholar
  22. 22.
    Gibbons GR, Wyrick S, Chaney SG (1989) Rapid reduction of tetrachloro (D, L, trans) 1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium. Cancer Res 49: 1402Google Scholar
  23. 23.
    Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase in glutathione synthesis. Proc Natl Acad Sci USA 89: 3070Google Scholar
  24. 24.
    Reference deletedGoogle Scholar
  25. 25.
    Habig WH, Jakoby WB (1981) Assays for differentiation of glutathione transferases. Methods Enzymol 77: 398Google Scholar
  26. 26.
    Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC (1993) Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53: 5225Google Scholar
  27. 27.
    Hamilton TC, Young RC, Mckoy WM, Grotzinger KR, Green JA, et al. (1983) Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors. Cancer Res 43: 5379Google Scholar
  28. 28.
    Hosking LK, Whelan RDH, Shellard SA, Bedford P, Hill BT (1990) An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumor cell lines. Biochem Pharmacol 40: 1833Google Scholar
  29. 29.
    Hospers GA, Mulder NH, de Jong B, de Ley L, Uges DR, Fichtinger-Schepman AM, Scheper RJ, de Vries EG (1988) Characterization of a human small cell lung carcinoma cell line with acquired resistance to cisdiamminedichloroplatinum(II) in vitro. Cancer Res 48: 6803Google Scholar
  30. 30.
    Hrubisko M, McGown AT, Fox BW (1993) The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents. Biochem Pharmacol 45: 253Google Scholar
  31. 31.
    Ishikawa T, Ali-Osman F (1993) Glutathione-associated cisdiamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 268: 20116Google Scholar
  32. 32.
    Lai G, Ozols R, Young R, Hamilton T (1989) Effect of glutathione on DNA repair in cisplatin resistant human ovarian cancer cell lines. J Natl Cancer Inst 81: 535Google Scholar
  33. 33.
    Mausda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, et al (1988) Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 48: 5713Google Scholar
  34. 34.
    Meijer C, Mulder NH, Timmer-Bosscha H, Wluiter WJ, Meersma GJ, de Vries EGE (1992) Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 52: 6885Google Scholar
  35. 35.
    Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR (1991) The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64: 215Google Scholar
  36. 36.
    Mistry P, Loh SY, Kelland LR, Harrap KR (1993) Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovariancarcinoma cell lines. Int J Cancer 55: 848Google Scholar
  37. 37.
    Nayak SK, O'Toole C, Price ZH (1977) A cell line from an anaplastic transitional cell carcinoma of human urinary bladder. Br J Cancer 35: 142Google Scholar
  38. 38.
    Pendyala L, Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning and biotransformation of oxaliplatin. Cancer Res 53: 5970Google Scholar
  39. 39.
    Pendyala L, Arakali Av, Sansone P, Cowens JW, Creaven PJ (1990) DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II). Cancer Chemother Pharmacol 27: 248Google Scholar
  40. 40.
    Pendyala L, Walsh JR, Huq MM, Arakali Av, Cowens JW, Creaven PJ (1990) Uptake and metabolism of iproplatin in murine L1210 cells. Cancer Chemother Pharmacol 27: 248Google Scholar
  41. 41.
    Perez RP, Hamilton TC, Ozols RF (1990) Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther 48: 19Google Scholar
  42. 42.
    Ponten J, Macintyre EH (1968) Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 74: 465Google Scholar
  43. 43.
    Rairkar A, Ali-Osman F (1992) Modulation of DNA ligase activities in a BCNU and cisplatin resistant human malignant astrocytoma cell line by glutathione depletion. Proc Am Assoc Cancer Res 33: 7Google Scholar
  44. 44.
    Richon VM, Schulte N, Eastman A (1987) Multiple mechanisms of cellular resistance to platinum coordination complexes. Cancer Res 47: 2056Google Scholar
  45. 45.
    Rigby CC, Franks LM (1970) A human tissue culture cell line from a transitional cell tumor of the urinary bladder: growth, chromosome pattern and ultrastructure. Br J Cancer 24: 746Google Scholar
  46. 46.
    Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, et al (1990) Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113Google Scholar
  47. 47.
    Smith E, Brock AP (1988) An in vitro study comparing the cytotoxicity of three platinum complexes with regard to the effects of thiol depletion. Br J Cancer 57: 548Google Scholar
  48. 48.
    Smith MT, Evans CG, Doane-Setzer P, Castro VM, Tahir MK, Mannervik B (1989) Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res 49: 2621Google Scholar
  49. 49.
    Teicher BA, Frei E III (1988) Drug resistance in mammalian cells. In: Gupta RS (ed) Anticancer and other drugs. CRC, Boca Raton, p 1Google Scholar
  50. 50.
    Teicher BA, Holdon SA, Kelly MJ, Shea TC, Cucchi CA, et al (1987) Characterization of a human squamous cell carcinoma cell line resistant to cis-diamminedichloroplatinum (II). Cancer Res 47: 388Google Scholar
  51. 51.
    Tew KD (1989) The involvement of glutathione-S-transferases in drug resistance. Anticancer Drugs 191: 103Google Scholar
  52. 52.
    Tew KD, Clapper ML (1988) Glutathione S-transferases and anticancer drug resistance. In: Woolley PV, Tew KD (eds) Mechanisms of drug resistance in neoplastic cells. Academic Press, New York, p 141Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • L. Pendyala
    • 1
  • P. J. Creaven
    • 1
  • R. Perez
    • 1
  • J. R. Zdanowicz
    • 1
  • D. Raghavan
    • 1
  1. 1.Department of Investigational Therapeutics, Division of MedicineRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations